Medicare beneficiaries may soon have access to weight loss medications at a significantly reduced cost. Starting in July 2026, eligible individuals can obtain GLP-1 prescriptions, such as Wegovy and Zepbound, for a flat fee of $50 per month. This is a major change for Medicare, which has historically not covered weight loss treatments. The new program, called the Medicare GLP-1 Bridge, aims to make these effective but often expensive medications more accessible to those struggling with obesity.

This initiative is particularly relevant for the nearly 40% of American adults who are clinically obese, as it could help improve health outcomes related to weight, such as heart disease and diabetes. To qualify, individuals must have a body mass index (BMI) of 27 or higher, along with certain health conditions, or a BMI of 35 or higher. The predictable $50 copayment is designed to ease the financial burden, especially since many current users report that the medications are difficult to afford.

However, the program is still in its early stages and has limitations. It will run as a pilot from July 2026 to December 2027, and the $50 copayment will not count toward the annual out-of-pocket maximum for Medicare Part D. Additionally, individuals on low-income subsidies may find the $50 copayment a significant barrier. While the program offers a promising way to access GLP-1 medications, the long-term sustainability and potential for broader coverage remain uncertain.

For those considering these medications, it’s essential to consult with a healthcare provider to understand eligibility and navigate the prior authorization process.

Source: superagingnews.com